- Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependence
- Study design allows for the assessment of the entirety of the short bowel syndrome patient population
- US IRB approval secured; study to include up to 50 sites in North America and Europe and remains on track with study initiation as early as end-of-year
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Nov 29, 2022
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers